Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Crucell   /   Crucell en Okairos

Crucell« Terug naar discussie overzicht

Crucell en Okairos

Volgen
18 Posts
| Omlaag ↓
  1. [verwijderd] 17 mei 2009 10:49
    Okairos Oct. 2005 PER.C6® Hepatitis C Phase I

    Rome, Italy, 23 April 2009

    Okairos Presents Hepatitis C Vaccine Interim Phase I Results Showing Specific T Cell Responses

    Okairos, a biopharmaceutical company developing genetic
    vaccines for major chronic infectious diseases, today announced the first interim results from
    a Phase I clinical trial of its hepatitis C virus (HCV) vaccine candidate, showing very strong
    HCV-specific T cell responses against multiple antigenic targets. This is the first such report for
    a prophylactic vaccine against HCV. These results are being presented at the Annual Meeting
    of the European Association for the Study of Liver Diseases (EASL) in Copenhagen on 23-26
    April 2009.
    The Phase I trial, which began in October 2008, is designed to assess the safety and immunogenicity
    of a novel Adenovirus-based vaccine candidate for the prophylaxis and immunotherapy of HCV
    infection. The candidate vaccine is composed of two non-cross-reacting replication-defective
    Adenovirus vectors with very low seroprevalence in humans, and encodes the non-structural
    (NS) proteins NS3-5 of HCV. The Phase I trial is a double-prime, heterologous boost, dose
    escalation study being performed at the University of Oxford, England on a total of 36 healthy
    volunteers aged 18-50. Subjects are primed with one of three doses of one Adenovirus vector
    and boosted 12 or 24 weeks later with the maximum safe dose of the other Adenovirus vector
    in a crossover design. The trial will be completed by the end of 2009.

    Prof. Paul Klenerman, Principal Investigator of the trial, said: “These initial clinical trial data are
    extremely encouraging and support the feasibility of developing a vaccine against HCV based
    on T cell induction, which appears to be a prerequisite for successful protection from the virus.
    We look forward to further important data from the trial following the booster phase.”
    Prof. Riccardo Cortese, CEO of Okairos, added, “These exciting interim results clearly demonstrate
    our vaccine’s ability to stimulate very strong T cell immune responses, at a level higher than
    in any previous human vaccine trial after one injection, and also much higher than the level
    seen in individuals who spontaneously clear the HCV infection. These data also provide further
    validation of our Adenovirus platform and rich vaccine pipeline.”

    Okairos is developing both a prophylactic and a therapeutic vaccine against the hepatitis C
    virus (HCV). The prophylactic vaccine is in a Phase I trial that will be completed by the end
    of 2009, and is scheduled to enter a Phase II trial in early 2010. The therapeutic vaccine will
    be tested on chronically infected patients in a Phase Ib trial to begin in June 2009.

    www.okairos.it/
  2. [verwijderd] 17 mei 2009 11:16
    quote:

    gocrucellgo schreef:

    Okairos Oct. 2005 PER.C6® Hepatitis C Phase I

    ...

    Rome, Italy, 23 April 2009

    Okairos Presents Hepatitis C Vaccine Interim Phase I Results Showing Specific T Cell Responses

    The Phase I trial, which began in October 2008, ...
    Wellicht 2 opeenvolgende phase I trials, beginnend in 2005 resp. 2008.
  3. [verwijderd] 17 mei 2009 11:21
    quote:

    maxen schreef:

    [quote=gocrucellgo]
    Okairos Oct. 2005 PER.C6® Hepatitis C Phase I

    ...

    Rome, Italy, 23 April 2009

    Okairos Presents Hepatitis C Vaccine Interim Phase I Results Showing Specific T Cell Responses

    The Phase I trial, which began in October 2008, ...
    [/quote]

    Wellicht 2 opeenvolgende phase I trials, beginnend in 2005 resp. 2008.
    Ik dacht licentie 2005 en phase 1 2008.
  4. flosz 17 mei 2009 11:24
    Okairos is a clinical stage biopharmaceutical company
    spun off from Merck, Inc. in 2007 and developing genetic vaccines for major chronic
    infectious diseases, using novel proprietary technology. The company’s laboratories are
    located in Rome and Naples, Italy, and its corporate headquarters in Basel, Switzerland.
    It currently has 16 employees. Okairos’ technology platform is centered on the development
    of new, potent Adenovirus vectors, derived from strains isolated from chimpanzees
    and used to encode and deliver prophylactic and therapeutic antigens. These vectors
    have several major advantages and hold promise in generating effective immune responses
    where existing vectors have failed. Okairos’ Adenovirus vector platform is being used
    to generate a pipeline of vaccines against a range of infectious diseases for which there
    is currently no effective vaccine, as well as for cancer.

    Okairos is led by
    Riccardo Cortese, MD, PhD
    CEO and co-founder, who spent many years
    at Merck, Inc. coordinating the efforts that
    led to the development of several novel
    antiviral drugs and vaccines which are now
    at various stages of clinical development.
    Dr. Cortese was a founder and the fi rst
    director of the Gene Expression Program
    at the European Molecular Biology Laboratory EMBL) in Heidelberg and is a professor of
    Molecular Biology at the Medical School of
    the University of Naples. He has published
    in leading scientifi c journals including Nature,
    Science and Cell, on a range of topics in
    immunology, molecular medicine and drug
    discovery.
    www.okairos.it/OkairosFS0904.pdf

    Leiden, The Netherlands, October 10, 2005 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) announced today that Merck & Co., Inc. (NYSE: MRK) has exercised its option to use Crucell's PER.C6® production technology to develop an adenovirus-based vaccine against hepatitis C (HCV). Crucell will receive a US$ 1 million (€ 0.8 million) exercise fee with the prospect of annual fees and milestone payments, plus royalties on net sales.
    investors.crucell.com/C/132631/PR/200...
  8. flosz 10 juni 2009 14:34
    AdCh3NSmut and Ad6NSmut

    The Latium Vaccine Pole
    Background, Technological Platforms, Research Projects

    PROPHILACTIC AND THERAPEUTIC HEPATITIS C VIRUS VACCINE
    PI: Alfredo Nicosia
    Institution: Okairós
    Address: Via dei Castelli Romani 22, 00040, Pomezia – Roma - ITALY
    Phone: +39-06-97246470
    E-mail: nicosia@okairos.it
    Introduction
    An effective vaccine for hepatitis C virus (HCV) is undoubtedly an area of unmet clinical need. Currently
    there is no vaccine available for either the prevention (prophylactic vaccination) or the treatment (therapeutic
    vaccination) of HCV and the currently available therapy is frequently ineffective.
    www.sta.uniroma2.it/stabulario/serviz...

    GTAC 144:
    A Phase 1 study to
    assess the safety and
    immunogenicity of
    new Hepatitis C virus
    vaccine candidate
    AdCh3NSmut and
    Ad6NSmut.
    Hep.C
    Centre for Clinical
    Vaccinology and Tropical
    Medicine, Churchill
    Hospital, Oxford
    Conditional
    Approval
    Dec 07
    Ad6
    AdCh3
    Gene:
    Multiple
    hepatitis
    antigens
    Cell Line: PER.C6
    www.dh.gov.uk/ab/GTAC/Publications/in...
  9. flosz 14 oktober 2009 09:05
    Research Area: Immunology
    Technology Exchange: Gene therapy
    Keywords: Hepatitis C, genotype-3, T cells, vaccine and therapy
    1. HCV infection consists of 6 major genotypes. HCV genotype-3 infection is now the dominant genotype in the UK.
    HCV genotype-3 infection is particularly responsive to current gold-standard therapies. The reasons for this are unknown but may relate to a favorable T cell response against this specific sub-type. Although there has been extensive research into HCV genotype-1 infection, little is known about HCV genotype-3. Currently we are evaluating T cell immunity to this strain in the context of acute disease, chronic disease and therapy. Furthermore identifying those T cell epitopes that are important in genotype-3 control will be essential for vaccine design, that aims to induce inter-genotype immunity.

    2. A recent award from the MRC will fund a phase Ib study into the use of adenoviral vectors (in collaboration with Okairos*), encoding HCV proteins, as a therapeutic vaccine for HCV infection. This study will begin in 2009 with the aim of inducing T cell responses during gold-standard therapy for HCV. Ultimately the aim will be to enhance the sustained virological rates of current therapy.
    www.ndm.ox.ac.uk/researcher/ellie-barnes

    * ism Alfredo Nicosia

    *********************

    hepatitis C
    (HCV) vaccine
    The hepatitis C virus (HCV) chronically affects 1 in 50 people worldwide, with 3-4 million new
    cases each year, including 30.000 in the U.S. HCV is the leading cause of chronic liver disease in the world
    and has been correlated with an increased risk of developing primary hepatocellular carcinoma. No vaccine is
    yet available. The current therapy is effective in only about half of the treated cases and carries the risk of severe side
    effects. Obstacles to the development of an effective prophylactic vaccine have included the ability of the virus to escape
    antibody immunosurveillance, as well as the lack of in-depth study of the immune response in HCV-infected individuals.
    Okairos’ scientists have shown that the magnitude of an early T cell response during acute HCV infection correlates with the outcome, with
    a strong T cell response found in those rare individuals who spontaneously clear the virus infection. The company’s candidate prophylactic and
    therapeutic vaccines are based on the 2000-amino-acid-long Non-Structural region of HCV. The Okairos vaccine protected chimpanzees
    from acute and chronic infection induced by a highly heterologous HCV virus.
    The vaccine is presently undergoing a Phase I dose escalation trial in healthy human volunteers for an assessment of its safety and
    immunogenicity. The results obtained so far with a single injection of chimp-derived Adenovirus vectors in humans showed
    an extremely strong T cell response, greater than any previously observed with a genetic vaccine.
    A Phase II trial of the prophylactic vaccine is scheduled for early 2010. The therapeutic vaccine will be
    tested on chronically infected patients in a Phase Ib trial to begin in June 2009

    Okairos obtained €14 million in grants from the NIH, the EU and the Wellcome Trust for
    the development and early clinical trials of the HCV and malaria vaccines. The company
    obtained a further €7.2 million from major life science venture capital funds in a Series A
    fi nancing round completed in February 2007, with the participation of LSP, BioMedInvest
    and Novartis Venture Funds. The funds raised are being used to fi nance the completion of
    clinical Phase I and II trials for malaria and Phase I and Ib trials for HCV.
  10. [verwijderd] 4 november 2009 12:11
    Procell92

    Okairos has developed a proprietary packaging cell line called PROCELL92, with better capability to support Adenovirus vector growth.

    PROCELL92 allows the efficient production of Adenovirus vectors that cannot be propagated in standard human HEK 293 or fetal PER C6 cells, because they encode proteins that interfere with the host cell metabolism (i.e. proteins with transmembrane domains or proliferative activity). In addition, PROCELL92 does not lead to the formation of replication-competent Adenovirus during vector propagation.

    Therefore, PROCELL92 represents the ultimate cell substrate for the production of any Adenovirus-based vaccine vector. The figure below shows the high level of productivity by PROCELL92 of an Adenovirus vector, encoding three toxic HCV proteins, which does not grow in 293 or PER C6 cells.


    www.okairos.it/e/inners.php?m=00044
  14. flosz 20 december 2009 20:16
    Participants are needed to help develop a vaccine against Hepatitis C
    Hepatitis C is a major cause of liver disease, worldwide - currently there is no vaccine available. A clinical trial is takling place at the Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Headington.
    Are you aged 18 to 50 years old? In good health, and never had Hepatitis C? Then you may be elegible to take part in this study.
    This study is based on visits to the out-patients clinic at the Churchill Hospital in Headington, Oxford.
    Volunteers will be compensated for their travel, time and blood donation. If you would like to know more about taking part in our studies please contact: VaccineTrials@well.ox.ac.uk xor call on (01865) 857401 (Study Coordinator).
    www.jenner.ac.uk/Volunteers/Hepatitis...
  15. flosz 22 april 2010 14:43
    Study of a Novel Therapeutic Vaccine for Hepatitis C Virus
    This study is currently recruiting participants.
    Verified by Okairos, April 2010

    HCV002TV is a Phase I study to ascertain the safety and immunogenicity of a novel vaccine against Hepatitis C virus (HCV) in chronically infected patients. The vaccine is based on the sequential delivery, by intramuscular route, of two different adenoviral vectors, of chimpanzee and human origin respectively, bearing the same genetic information for HCV antigens (NS region).
    The two recombinant vaccine vectors, called AdCh3NSmut and Ad6NSmut, are weakened and unable to multiply within the body; they are designed to induce an immune response against HCV proteins. AdCh3NSmut and Ad6NSmut are being used in the ongoing HCV001 study in healthy volunteers with very good safety and immunogenicity results.
    HCV002TV is a dose-escalation study; the AdCh3NSmut is administered as priming vaccination and Ad6NSmut as boosting vaccination.
    The trial includes:
    • Arm A, in which vaccinated patients are into Interferon-ribavirin therapy (the gold standard therapy for hepatitis C);
    • Arm B, in which vaccinated patients are not into therapy.
    Hepatitis C Biological: AdCh3NSmut; Ad6NSmut Phase I

    Estimated Enrollment: 24
    Study Start Date: November 2009
    Estimated Study Completion Date: May 2012
    Estimated Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
    www.clinicaltrials.gov/ct2/show/NCT01...
    *************
    A Study of a New Candidate Vaccine Against Hepatitis C Virus (HCV)
    This study is currently recruiting participants.
    Verified by Okairos, February 2010
    HCV001 is a Phase I study to ascertain the safety and immunogenicity of a novel vaccine against Hepatitis C virus (HCV). The vaccine is based on the sequential delivery, by intramuscular route, of two different adenoviral vectors, of human and chimpanzee origin respectively, bearing the same genetic information for HCV antigens (NS region).
    The two recombinant vectors, called Ad6NSmut and AdCh3NSmut, are weakened and unable to multiply within the body; they are designed to induce an immune response against HCV proteins. Although Ad6NSmut and AdCh3NSmut have never been given to humans before this trial, promising results have been obtained in non-human studies.
    The HCV001 study is designed to explore different prime-boost regimes concerning dose, order and interval of administration of Ad6NSmut and AdCh3NSmut.
    Hepatitis C Biological: Ad6NSmut; AdCh3NSmut
    Biological: AdCh3NSmut; Ad6NSmut Phase I

    Estimated Enrollment: 50
    Study Start Date: July 2007
    Estimated Study Completion Date: December 2010
    Estimated Primary Completion Date: June 2010
    www.clinicaltrials.gov/ct2/show/NCT01...

  16. flosz 22 april 2010 14:49
    UK Latest summary of GTAC-approved research
    GTAC=Gene Therapy Advisory Committee

    October 2009.

    A Phase 1 study to assess the safety and immunogenicity of new Hepatitis C virus vaccine candidate AdCh3NSmut and Ad6NSmut.
    EudraCT 2007-004259-12
    Hepatitis C
    Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road,Headington,
    Oxford OX3 7LJ, Welcome Trust Clinical Research Facility, University Hospital Birmingham NHS Trust
    Cell line: PER.C6
    NO. OF PATIENTS: - of 36

    A phase 1 study to assess the safety and immunogenicity of Ad6NSmut and AdCh3NSmut in patients with hepatitis C virus infection
    EurdraCT No: 2008-006127-32
    Hep C
    Dr Eleanor Barnes University of Oxford
    Nuffield Dept of Medicine Peter Medwar Building for Pathogen Research South Parks Road Oxford
    Provisional Opinion 04/09
    Human Adenovirus Type 6 serotype pluse Chimpanzee Adenovirus Type 3 serotype
    Cell line: PERC.6

    Verder:
    Gene directed enzyme prodrug therapy for the treatment of head and neck cancer (Phase I intratumoral)
    Head and Neck Cancer
    Queen Elizabeth Hospital, Birmingham; RoyalMarsden Hospital, London
    Nitroreductase
    Cell line: PER-C6
    NO. OF PATIENTS: 7 of 30
    CLOSED

    Gene directed enzyme prodrug therapy for the treatment of liver cancer (Phase I intratumoral)
    Liver Cancer
    Queen Elizabeth Hospital, Birmingham
    Nitroreductase
    Cell line: PER-C6
    NO. OF PATIENTS: 25 of 30
    CLOSED

    The safety and effects of Ad5.1 mediated human FGF-4 gene transfer in patients with peripheral arterial occlusive disease (PAOD)
    Peripheral Arterial Occlusive Disease
    St George’s Hospital, London
    FGF-4
    Cell line: PER-C6
    NO. OF PATIENTS: 13 (2 UK) of 30
    CLOSED

    Gene directed enzyme prodrug therapy for the treatment of prostate cancer (Phase I intratumoral)
    Prostate Cancer
    Queen Elizabeth Hospital, Birmingham; Freeman Hospital Newcastle; St James’s University Hospital, Leeds
    Nitro reductase
    Cell line: PER-C6
    NO. OF PATIENTS: 39 of 44
    CLOSED

    A Phase 1 clinical trial of a replication defective Ad5 vector expressing nitroreductase and GMCSF (AdNRGM) given via brachytherapy, followed by CB1954 in patients with locally relapsed, prostate cancer.
    EudraCT No: 2007-007041-13
    Prostate cancer
    Queen Elizabeth Hospital at UHB NHS Foundation Trust
    Cell line: PERC.6

    Zie ook no.97 op p. 24
    tinyurl.com/247d67p
  17. flosz 22 april 2010 14:52
    PHASE I TRIAL OF A HIGHLY IMMUNOGENIC T CELL VACCINE FOR HEPATITIS C VIRUS BASED ON NOVEL ADENOVIRAL VECTORS FROM RARE SEROTYPES
    A. Folgori1, E. Barnes2, S. Aston2,3, K. Smith2, A. Brown2, M. Ambrosio4, V. Ammendola4, M. Bartiromo4, S. Capone4, M. Naddeo4, A. Sparacino4, L. Siani4, C. Traboni4, S. Colloca4, A. Nicosia4, R. Cortese4, P. Klenerman2
    1Immunology, Okairos srl, Naples, Italy, 2Oxford University, 3The Jenner Institute, Oxford, UK, 4Okairos srl, Naples, Italy

    Background and aims: Hepatitis C virus (HCV) infection currently lacks an effective vaccine for prophylaxis or immunotherapy. The correlates of protective immunity in HCV infection are not fully defined. However, the strength, breadth and duration of the HCV specific T cell immune response clearly play a critical role in determining disease outcome. We have previously shown that a vaccine inducing T cells specific for non-structural proteins of HCV (NS) protected chimpanzees from chronic infection after challenge with a heterologous HCV viral strain. Translating these findings into man is critical. We therefore designed a Phase I study to assess the induction of NS protein specific T cell immunity in healthy human donors.
    Methods: We generated an HCV vaccine composed of two non cross-reacting replication-defective Adenovirus vectors of low sero-prevalence: human Adenovirus 6 and a novel simian Adenovirus 3. Each vector encodes 1985 amino acids derived from the NS3-5 region of a genotype 1b strain. Healthy volunteers aged 18-50 are enrolled in a double prime, heterologous boost dose escalation study (from 5x108 to 2.5x1010 viral particles). Volunteers are primed with two doses of one Adeno vector and boosted 12 or 24 weeks later with the maximum safe dose of the other Adeno vector in a crossover design. Immunogenicity is measured by ex-vivo IFNg ELIspot and proliferation assays.
    Results: Both vaccine vectors induced HCV specific T cell responses at the lowest doses administered. Frequency and potency of the responses increased at the medium dose, reaching up to 3,000 spots per million peripheral blood mononuclear cells. Responses were generally multi-specific and in some cases targeted all of the six pools of peptides covering the whole NS region. In addition, proliferative responses to different NS proteins were readily detected. To date, all tested doses were very well tolerated.
    Conclusions: We have generated a novel T cell vaccine based on adenovirus vectors from rare serotype expressing HCV NS proteins that is safe in man, highly immunogenic even at sub-maximal doses, and which readily induces responses against multiple antigenic targets.

    Okairos &Novartis:
    tinyurl.com/258s7ew
    With this project two vaccine companies in Europe, OKAIROS (a Biotech company created as a spin-off from Merck Inc.) and Novartis Vaccines & Diagnostics (ex-Chiron), join their efforts with several European groups and our institution VACSERA from Egypt to develop efficacious preventative and therapeutic Hepatitis C virus (HCV) vaccines.
    LSHB-2006-037435
    New preventive and therapeutic Hepatitis C vaccines: from pre-clinical to phase I
    1 February 2007 To 31 February 2011
    www.vacsera.com/R_&_D.html

    Novartis Venture Funds
    Okairos AG
    Riccardo Cortese, Basel, CH
    www.okairos.it (This site is temporarily unavailable. We will come back as soon as possible).
    Okairos is a Swiss based vaccine company, with a subsidiary in Italy, developing vaccines for mutating viruses. Its innovative viral adenovirus T cell platform allows to develop novel vaccines for the prevention and treatment of major life-threatening infections, including malaria and hepatitis C. Company has entered clinical stage.
    www.venturefund.novartis.com/index.ph...

    WHO, Hepatitis C Virus.
    Virally vectored vaccines:
    Replicative defective adenoviral vectors that are genetically engineered to encode the non-structural proteins (NS3-NS5B) of a genotype-1b HCV strain have been developed by Okairos (Rome, Italy), and are currently in phase I clinical trials (Oxford, UK). This follows earlier studies in chimpanzees using a heterologous prime boost regimen of adenoviral/DNA (electroporated plasmid) vectors encoding the HCV NS proteins. This strategy induced broad CD8+ and CD4+ HCV specific T cell responses in 4/5 animals that were protected from heterologous viral challenge [29] . Since anti-adenoviral antibodies can limit the efficacy of these vectors, a number of adenoviral vectors derived from rare human adenoviral serotypes and also from chimpanzee adenovirus, to which humans have been rarely exposed, have been developed. A Phase I study of healthy volunteers, using a double prime/heterologous boost with two different adenoviral vectors has recently been shown to be highly immunogenic. A therapeutic vaccine approach using the same vectors in combination with interferon and ribavirin is currently underway in Oxford, UK.
    www.who.int/vaccine_research/diseases...
18 Posts
|Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
EBUSCO HOLDING 1,297 +0,23 +21,05%
HEIJMANS KON 30,900 +1,25 +4,22%
BAM 4,160 +0,13 +3,17%
THEON INTERNAT 11,300 +0,28 +2,54%
Fugro 17,390 +0,39 +2,29%
ASML 677,900 +13,80 +2,08%
NX FILTRATION 4,110 +0,08 +1,99%
CM.COM 6,070 +0,11 +1,85%
SBM Offshore 17,100 +0,30 +1,79%
Arcadis 63,750 +1,10 +1,76%
BESI 116,000 +2,00 +1,75%
SHELL PLC 31,035 +0,50 +1,64%
ForFarmers 3,245 +0,04 +1,25%
AMG Critical Materials N.V. 14,610 +0,18 +1,25%
Van Lanschot Kempen NV 43,200 +0,50 +1,17%
Sif Holding 12,520 +0,14 +1,13%
Akzo Nobel 58,100 +0,58 +1,01%
EXOR NV 93,750 +0,90 +0,97%
Eurocommercial Properties 23,350 +0,20 +0,86%
IMCD 142,950 +1,15 +0,81%
UMG 23,290 +0,16 +0,69%
Corbion 22,180 +0,14 +0,64%
Wolters Kluwer 161,300 +1,00 +0,62%
ING 14,640 +0,08 +0,52%
NSI 19,700 +0,10 +0,51%
RENEWI 9,710 +0,04 +0,41%
Ahold Delhaize 32,810 +0,13 +0,40%
ASCX 1.231,85 +4,43 +0,36%
Wereldhave 14,060 +0,04 +0,29%
OCI 11,110 +0,03 +0,27%
Aegon 6,060 +0,02 +0,26%
TKH 30,860 +0,08 +0,26%
AEX 889,92 +2,27 +0,26%
Vopak 43,240 +0,10 +0,23%
RANDSTAD NV 42,100 +0,08 +0,19%
ALLFUNDS GROUP 5,660 +0,01 +0,18%
RELX 45,220 +0,06 +0,13%
ASMI 512,400 +0,60 +0,12%
AALBERTS NV 36,440 +0,02 +0,05%
JDE PEET'S 18,870 +0,01 +0,05%
Avantium 2,060 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
Vastned 23,250 -1,50 -6,06%
TomTom 4,950 -0,30 -5,71%
Pharming 0,699 -0,03 -3,45%
JUST EAT TAKEAWAY 15,230 -0,49 -3,12%
NN Group 42,630 -1,01 -2,31%
AZERION 1,192 -0,03 -2,30%
B&S Group SA 4,340 -0,09 -1,92%
Philips Koninklijke 25,110 -0,49 -1,91%
Kendrion 10,240 -0,18 -1,73%
Alfen N.V. 11,060 -0,19 -1,69%
INPOST 16,360 -0,25 -1,51%
FASTNED 20,900 -0,30 -1,42%
Accsys 0,577 -0,01 -1,37%
SIGNIFY NV 21,520 -0,28 -1,28%
WDP 20,680 -0,24 -1,15%
Nedap N.V. 53,000 -0,60 -1,12%
Heineken 69,880 -0,76 -1,08%
UNILEVER PLC 56,560 -0,60 -1,05%
Aperam 26,920 -0,28 -1,03%
Basic-Fit 20,840 -0,20 -0,95%
ArcelorMittal 23,950 -0,22 -0,91%
ADYEN NV 1.401,800 -11,60 -0,82%
Air France-KLM 7,254 -0,03 -0,47%
ABN AMRO BANK N.V. 14,660 -0,06 -0,41%
CTP 15,140 -0,06 -0,39%
DSM FIRMENICH AG 104,400 -0,40 -0,38%
PROSUS 39,175 -0,15 -0,37%
ACOMO 17,440 -0,06 -0,34%
Fagron 18,300 -0,06 -0,33%
KPN 3,665 -0,01 -0,33%
Galapagos 26,300 -0,08 -0,30%
PostNL 1,028 0,00 -0,19%
Flow Traders 20,860 -0,04 -0,19%
Sligro 10,720 -0,02 -0,19%
ASR Nederland 44,980 -0,08 -0,18%
Brunel 8,840 -0,01 -0,11%
AMX 870,16 -0,97 -0,11%
vlag naam koers verschil relatief verschil
AEX 889,92 +2,27 +0,26%
AEX GR 3.490,57 +8,90 +0,26%
Germany40^ 20.029,70 +96,08 +0,48%
FTSE 100 8.359,41 +46,52 +0,56%
EURO50 4.881,88 +29,07 +0,60%
US30^ 44.779,80 -17,60 -0,04%
Nasd100^ 21.173,80 +8,60 +0,04%
US500^ 6.047,01 -0,75 -0,01%
Japan225^ 39.176,70 +557,10 +1,44%
VD-NEW 14,23 -0,63 -4,24%
#/^ Index indications calculated real time, zie disclaimer